Adamis Pharmaceuticals Announces Pricing of Public Offering

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock

SAN DIEGO, Jan. 9, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP ), a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology, announced today the pricing of its previously announced underwritten public offering of 2,000,000 shares of common stock at a public offering price of $5.00 per share, resulting in gross proceeds of approximately $10,000,000.

The offering is expected to close on January 14, 2015, subject to the satisfaction of customary closing conditions. The company has also granted the underwriters a 30-day option to purchase up to 300,000 additional shares of common stock to cover over-allotments, if any.

Oppenheimer & Co. Inc. is acting as the sole book-running manager for the proposed offering. CRT Capital Group LLC, Maxim Group LLC and Mizuho Securities USA Inc. are acting as co-managers for the offering.

The securities described above are being offered by the company pursuant to a "shelf" registration statement on Form S-3 (file No. 333-196976) previously filed with and declared effective by the Securities and Exchange Commission (SEC) on July 2, 2014. A final prospectus supplement and an accompanying prospectus related to the offering will be filed with the SEC and will be available on the SEC's website located at www.sec.gov . When available, copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained by contacting Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY 10004, or by telephone at (212) 667-8563, or by email at EquityProspectus@opco.com . 

Before investing in the offering, you should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the company has filed with the SEC that are incorporated by reference in the prospectus supplement and the accompanying prospectus, which provide more information about the company and the offering. 

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Adamis Pharmaceuticals Corporation

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology.  The company's current specialty pharmaceutical product candidates include the Epinephrine Injection PFS syringe product for use in the emergency treatment of anaphylaxis, APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease, and APC-3000, an HFA inhaled nasal steroid product for the treatment of allergic rhinitis. The company's vaccine product candidates and cancer drug product candidates under research and development include TeloB-VAX, a cell-based therapeutic cancer vaccine and three drugs, APC-100, APC-200, and APC-300, for the treatment of prostate cancer.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the public offering and the intended use of proceeds from the offering and statements about the progress of the commercialization of its epinephrine pre-filled syringe product and the development of the company's product candidates.  The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.  These forward-looking statements also are subject to risks, uncertainties and assumptions, including those detailed from time to time in the company's filings with the SEC, and represent the company's views only as of the date they are made and should not be relied upon as representing the company's views as of any subsequent date.  The company's actual results may differ materially from those contemplated by these forward-looking statements.  Except to the extent required by law, the company does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this press release.

Contact Adamis Mark Flather Director, Investor Relations & Corporate Communications (858) 412-7951

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Biotech Hit or Miss: Trials and Tribulations

Updated Category News Views 45

Biotech's Roller Coaster: Triumphs and Setbacks Ah, the biotech sector—it's a bit like jumping on a bull, ain't it? You barely hang on when the beast bucks. Monday's market action was downright wild. The S&P 500 didn't have a party, tumbling 1.92%, and the Nasdaq wasn't any friendlier, plummeting 2.49%. Yet, inside this storm, we see some biotech names either catching...

Continue Reading
Monotype Unveils Font Tool for Adobe: A Game-Changer?

Updated Category News Views 106

Monotype Connect: Fonts Meet Convenience Imagine fighting through a blizzard with a flashlight. That's how designers juggle fonts without a central tool. Well, Monotype's got them covered with the new Connect panel for Adobe apps—a beacon of efficiency spotted at Adobe MAX 2026 in Miami Beach. Efficiency and Brand Unity: Partners in Design Now, here’s why this isn’t...

Continue Reading
Home Energy Tips: Embrace the Electrical Panel Shift

Updated Category News Views 52

Why Electrical Panels Matter More Than Ever Back in the day, electrical panels weren't exactly the star of the homeowner show. But times have changed, and those previously mundane boxes of switches and wires now demand a spotlight. Shifts in modern lifestyles have catapulted electrical systems into the spotlight, making upgrades a pressing conversation topic for savvy...

Continue Reading
Lululemon Faces Class Action over Alleged Missteps

Updated Category News Views 39

Trouble Brewing for Lululemon Y'ever get that gut feeling when something doesn't smell right? Well, Lululemon Athletica (NASDAQ: LULU) investors are probably feeling that now. A class action's kicking up dust over what some are saying was a downright bumpy ride. The brainiacs at Robbins LLP urge those who've lost bucks riding the LULU train to step forward ahead of the...

Continue Reading
Panasonic Showcases Rugged Tech at NATO Edge 26

Updated Category News Views 56

Panasonic Heads to Turkey with Tactical Tech Panasonic's got its sights set on proving a point at NATO Edge 26, busting out its TOUGHBOOK line and showing just how these rugged laptops aren't just tough, but also strategically essential. From November 17th through 19th, down in Turkey, these devices are taking the spotlight as they embrace the operational challenges of...

Continue Reading
Endava's Audit Scandal: Investors Face Crucial Decision

Updated Category News Views 111

Endava's Unexpected Crisis: What's Happening? It's the kind of mess no investor wants to wake up to: on October 28, 2026, Endava plc (NYSE: DAVA) laid out a smorgasbord of screw-ups that have left the market reeling. The company's last few days were a whirlwind, featuring the CFO's abrupt exit and the CEO swap. This shake-up didn't happen in isolation—the announcement...

Continue Reading
HLTH USA 2026 Spotlights AI and Health Innovation

Updated Category News Views 77

The Pulse of Innovation at HLTH USA 2026 Diving headfirst into the heart of healthcare innovation, HLTH USA 2026 kicked off with gusto in Las Vegas. Discussions are swirling around AI advancements and the next generation of payer-provider collaboration. Who knew healthcare could be this thrilling? The event is already shaping up to be a powerhouse of change, buzzing with...

Continue Reading
Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 148

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
Lear Gears Up for Goldman Sachs Event Spotlight

Updated Category News Views 45

Lear Prepares for the Big Stage in London Autumn leaves and industry insights are falling in full swing as Lear Corporation gets its ducks in a row for the upcoming Goldman Sachs 18th Annual Industrials & Autos Week. Kicking off on December 3, 2026, this gathering in London isn't just another checkbox on their corporate calendar—it's a prime moment in the spotlight....

Continue Reading
Copper Peptides Shine in New Renue Blue Cream

Updated Category News Views 83

Renue By Science's Ambitious Skincare Launch Alright, we've got a big player stepping up in the realm of skincare with a new face cream packed tightly with science-backed goodies. Renue By Science is revamping their game by anchoring their new Renue Blue Face Cream around the star of the moment: copper tripeptide-1, also known as GHK-Cu. This is more than a beauty gloss...

Continue Reading

Top 5 Most Recently Viewed Articles

Blain’s Farm & Fleet Shines in Newsweek’s Best Online Shops

Updated Category News Views 97

Blain’s Farm & Fleet Achieves Recognition for Online Excellence Blain's Farm & Fleet, a well-respected name in retail, has been honored as one of Newsweek’s Best Online Shops for 2025. This recognition marks the fourth consecutive year the company has earned this prestigious title, reflecting its unwavering commitment to quality and service across its online platform....

Continue Reading
Statkraft AS Secures NOK 3 Billion Through Commercial Paper

Updated Category News Views 127

Statkraft AS Secures Significant Funding Statkraft AS has successfully issued a commercial paper totaling NOK 3.0 billion, showcasing the company's strategic approach to financing. This financial instrument offers a coupon rate of 3M NIBOR plus 0.205%, reflecting favorable conditions in financial markets. Details of the Commercial Paper The commercial paper is designed...

Continue Reading
Soleno Therapeutics Launches $100 Million Stock Buyback Program

Updated Category News Views 143

Soleno Therapeutics Initiates Major Buyback Program Soleno Therapeutics Inc. (NASDAQ: SLNO) has announced a significant development in its corporate strategy by launching a $100 million share repurchase program. This move comes as the company seeks to enhance shareholder value amidst an environment where its stock has been deemed undervalued by market analysts. Details of...

Continue Reading
Brentwood Associates Launches $410 Million Fund for Watermill

Updated Category News Views 383

Overview of the New Continuation Fund Brentwood Associates, a leading private equity firm known for its strategic and growth-oriented investments, has officially closed an impressive $410 million continuation fund aimed at fueling the expansion of Watermill Express, LLC. This fund's purpose is to enhance the operational capabilities of Watermill Express, a prominent...

Continue Reading
Great Lakes Dredge & Dock Corporation Upgraded to B- Rating

Updated Category News Views 105

Great Lakes Dredge & Dock Corporation Receives S&P Upgrade Great Lakes Dredge & Dock Corporation ("Great Lakes" or the “Company”) (NASDAQ: GLDD), the leading provider of dredging services in the United States, has announced a notable upgrade to its issuer credit rating by S&P Global Ratings. The rating has been elevated from “CCC+” to “B-,” signaling a...

Continue Reading